Loading patent…
AssigneesNserm (Institut National De La Santé Et De La Recherche MéDicale), Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique-HôPitaux De Paris (Aphp)
InventorGuillaume CANAUD
Estimating the term…
The invention relates to a method for treating mitochondrial genetic diseases. The inventors have worked with primary fibroblasts from patients and control individuals and collected protein lysates for western blotting. Importantly, they observed that the genetic mitochondrial disorders, show a significant increase in phosphorylation of ribosomal protein S6 (pS6) compared to control fibroblasts, indicative of hyperactivated mTOR signaling. Patients with mitochondrial disorders and controls cells were treated for 48 hours with DMSO or BYL719. All lines from patients with mitochondrial diseases show reduced membrane potential, determined by TMRE staining intensity, and abnormal morphology, fragmentation and the presence of depolarized (low TMRE staining) mitochondria. Treatment with BYL719 attenuated these phenotypes in all MELAS fibroblasts while having no overt impact on the control cells. Similar experiments using flow cytometry confirmed membrane potential (TMRE) rescue by BYL719 treatment in MELAS fibroblasts.
A method for treating mitochondrial genetic diseases in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of a PI3K inhibitor.
A method of screening a drug suitable for the treatment of mitochondrial genetic diseases comprising i) providing a test compound ii) determining the ability of said test compound to inhibit the activity of PI3K, and, based on results from the determining step, iii) identifying the test compound as a suitable drug.
Dependencies are inferred from the claim text.